{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:25:50Z","timestamp":1787185550239,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006796","name":"Purdue University | Herbert C. Brown Center for Borane Research, Purdue University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006796","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brown Center for Immunotherapy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02784-4","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:02:12Z","timestamp":1787184132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-cell multiomics reveals exosome-mediated reprogramming and clonotypic remodeling of T cells in triple-negative breast cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Sanam","family":"Rezaei Benam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Maleknia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-438X","authenticated-orcid":false,"given":"Lionel","family":"Apetoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-0733","authenticated-orcid":false,"given":"Reza","family":"Shahbazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2784_CR1","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.2217\/nnm-2017-0081","volume":"12","author":"R Shahbazi","year":"2017","unstructured":"Shahbazi, R. et al. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer. Nanomedicine 12, 1961\u20131973 (2017).","journal-title":"Nanomedicine"},{"key":"2784_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-010-1293-1","volume":"125","author":"SK Pal","year":"2011","unstructured":"Pal, S. K., Childs, B. H. & Pegram, M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res. Treat. 125, 627\u2013636 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"2784_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: pitfalls and progress. npj Breast Cancer 8, 95 (2022).","journal-title":"npj Breast Cancer"},{"key":"2784_CR4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"KA Won","year":"2020","unstructured":"Won, K. A. & Spruck, C. Triple-negative breast cancer therapy: current and future perspectives. Int. J. Oncol. 57, 1245\u20131261 (2020).","journal-title":"Int. J. Oncol."},{"key":"2784_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrc3896","volume":"15","author":"EC Dietze","year":"2015","unstructured":"Dietze, E. C. et al. Triple-negative breast cancer in African-American women: disparities versus biology. Nat. Rev. Cancer 15, 248\u2013254 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"2784_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3390\/cancers14051253","volume":"14","author":"M Bou Zerdan","year":"2022","unstructured":"Bou Zerdan, M. et al. Triple-negative breast cancer: updates on classification and treatment in 2021. Cancers 14, 1253 (2022).","journal-title":"Cancers"},{"key":"2784_CR7","doi-asserted-by":"publisher","first-page":"e0229955","DOI":"10.1371\/journal.pone.0229955","volume":"15","author":"TF He","year":"2020","unstructured":"He, T.F. et al. Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: evolution of tumor immune profiles and patient prognosis. PLoS ONE 15, e0229955 (2020).","journal-title":"PLoS ONE"},{"key":"2784_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/cancers15030767","volume":"15","author":"C Valenza","year":"2023","unstructured":"Valenza, C. et al. Tumor infiltrating lymphocytes across breast cancer subtypes: current issues for biomarker assessment. Cancers 15, 767 (2023).","journal-title":"Cancers"},{"key":"2784_CR9","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand, Y. et al. Immune checkpoint inhibitors in cancer therapy. Curr. Oncol. 29, 3044\u20133060 (2022).","journal-title":"Curr. Oncol."},{"key":"2784_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41423-020-0391-1","volume":"17","author":"X Zhou","year":"2020","unstructured":"Zhou, X. et al. The function and clinical application of extracellular vesicles in innate immune regulation. Cell. Mol. Immunol. 17, 323\u2013334 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"2784_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01810-z","volume":"26","author":"S Safaei","year":"2024","unstructured":"Safaei, S. et al. Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies. Breast Cancer Res. 26, 57 (2024).","journal-title":"Breast Cancer Res."},{"key":"2784_CR12","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/cells11121946","volume":"11","author":"QH Xie","year":"2022","unstructured":"Xie, Q. H. et al. Exosome-mediated immunosuppression in tumor microenvironments. Cells 11, 1946 (2022).","journal-title":"Cells"},{"key":"2784_CR13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1172\/JCI81136","volume":"126","author":"TL Whiteside","year":"2016","unstructured":"Whiteside, T. L. Exosomes and tumor-mediated immune suppression. J. Clin. Invest. 126, 1216\u20131223 (2016).","journal-title":"J. Clin. Invest."},{"key":"2784_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ejca.2013.01.017","volume":"49","author":"K O\u2019Brien","year":"2013","unstructured":"O\u2019Brien, K. et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur. J. Cancer 49, 1845\u20131859 (2013).","journal-title":"Eur. J. Cancer"},{"key":"2784_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-022-00763-8","volume":"23","author":"EI Buz\u00e1s","year":"2023","unstructured":"Buz\u00e1s, E. I. The roles of extracellular vesicles in the immune system. Nat. Rev. Immunol. 23, 236\u2013250 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2784_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.4049\/jimmunol.2400335","volume":"213","author":"TL Whiteside","year":"2024","unstructured":"Whiteside, T. L. Tumor-derived exosomes and antitumor immunity. J. Immunol. 213, 923\u2013931 (2024).","journal-title":"J. Immunol."},{"key":"2784_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02528-8","volume":"22","author":"V Karpisheh","year":"2022","unstructured":"Karpisheh, V. et al. The role of Th17 cells in the pathogenesis and treatment of breast cancer. Cancer Cell Int. 22, 108 (2022).","journal-title":"Cancer Cell Int."},{"key":"2784_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03525-9","volume":"24","author":"MT Anvar","year":"2024","unstructured":"Anvar, M. T. et al. Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies? Cancer Cell Int. 24, 355 (2024).","journal-title":"Cancer Cell Int."},{"key":"2784_CR19","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","volume":"12","author":"LV Riella","year":"2012","unstructured":"Riella, L. V. et al. Role of the PD-1 pathway in the immune response. Am. J. Transplant. 12, 2575\u20132587 (2012).","journal-title":"Am. J. Transplant."},{"key":"2784_CR20","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","volume":"25","author":"A Angelin","year":"2017","unstructured":"Angelin, A. et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 25, 1282\u20131293.e7 (2017).","journal-title":"Cell Metab."},{"key":"2784_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"2784_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.07.009","volume":"182","author":"A Hoshino","year":"2020","unstructured":"Hoshino, A. et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell 182, 1044\u20131061.e18 (2020).","journal-title":"Cell"},{"key":"2784_CR23","doi-asserted-by":"publisher","first-page":"e202201848","DOI":"10.26508\/lsa.202201848","volume":"6","author":"K Boufea","year":"2022","unstructured":"Boufea, K. et al. Single-cell RNA sequencing of human breast tumour-infiltrating immune cells reveals a \u03b3\u03b4 T-cell subtype associated with good clinical outcome. Life Sci. Alliance 6, e202201848 (2022).","journal-title":"Life Sci. Alliance"},{"key":"2784_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0165-2478(03)00128-7","volume":"89","author":"S Utsugi-Kobukai","year":"2003","unstructured":"Utsugi-Kobukai, S. et al. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol. Lett. 89, 125\u2013131 (2003).","journal-title":"Immunol. Lett."},{"key":"2784_CR25","doi-asserted-by":"publisher","first-page":"115207","DOI":"10.1016\/j.biopha.2023.115207","volume":"165","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. The role of lncRNAs and exosomal lncRNAs in cancer metastasis. Biomed. Pharmacother. 165, 115207 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"2784_CR26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/s43018-024-00862-6","volume":"5","author":"I Wortzel","year":"2024","unstructured":"Wortzel, I. et al. Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression. Nat. Cancer 5, 1815\u20131833 (2024).","journal-title":"Nat. Cancer"},{"key":"2784_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01362-1","volume":"15","author":"S Maleknia","year":"2025","unstructured":"Maleknia, S. et al. Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression. Blood Cancer J. 15, 162 (2025).","journal-title":"Blood Cancer J."},{"key":"2784_CR28","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.1016\/j.ymthe.2025.08.020","volume":"33","author":"S Benam","year":"2025","unstructured":"Benam, S. et al. Enhanced hematopoietic stem cell self-renewal and engraftment through human lung exosomal communication. Mol. Ther. 33, 5704\u20135720 (2025).","journal-title":"Mol. Ther."},{"key":"2784_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-021-01336-8","volume":"19","author":"MD Luecken","year":"2022","unstructured":"Luecken, M. D. et al. Benchmarking atlas-level data integration in single-cell genomics. Nat. Methods 19, 41\u201350 (2022).","journal-title":"Nat. Methods"},{"key":"2784_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"2784_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0844-5","volume":"16","author":"G Finak","year":"2015","unstructured":"Finak, G. et al. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).","journal-title":"Genome Biol."},{"key":"2784_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"2784_CR33","first-page":"D148","volume":"48","author":"HY Huang","year":"2020","unstructured":"Huang, H.Y. et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. Nucleic Acids Res. 48, D148\u2013D154 (2020).","journal-title":"Nucleic Acids Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02784-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02784-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02784-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:02:13Z","timestamp":1787184133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02784-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2784"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02784-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"339"}}